Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Sep-23
- 20-Jun-24
- 18-Jul-24
- 15-Aug-24
- 13-Sep-24
Select bar for recommendation details.
Recommendations | 13-Sep-24 | |
---|---|---|
Buy | 0 | |
Outperform | 1 | |
Hold | 9 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 8 analysts offering 12 month price targets for Revance Therapeutics Inc have a median target of 6.66, with a high estimate of 25.00 and a low estimate of 6.00. The median estimate represents a 13.85% increase from the last price of 5.85.
High | 327.4% | 25.00 |
Med | 13.8% | 6.66 |
Low | 2.6% | 6.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate | +0.65% |
Average growth rate | -3.47% |
More ▼
Revenue history & estimates in USD
Average growth rate | +5.23% |
Average growth rate | +1,041.31% |
More ▼